Evaluation of Siddha Medicine Aavarai Vithaadhi Chooranam in the Management of Type 2 Diabetes (Madhumegam)

Single centric Phase II open clinical trial in Madhumegam (type II diabetes mellitus) with the Siddha medicine Aavarai Vithaadhi Chooranam - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/105397

Enrollment

Registered

2026-03-05

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications

Interventions

Intervention1: Aavarai Vithaadhi Chooranam: 100 gms of Cassia auriculata seeds and required quantity of juices of Ficus racemosa, Terminalia arjuna, Phyllanthus emblica, Asparagus racemosus, Musa para

Eligibility

Inclusion criteria

Inclusion criteria: HbA1c : 6-10 percent UKPDS Risk Score Within 10-25 percent

Exclusion criteria

Exclusion criteria: K/H/O Hypertension Smoker Insulin Dependent Diabetes Mellitus Vulnerable Population

Design outcomes

Primary

Measure	Time frame
The outcome is mainly assessed by : Reduction of HbA1C level after taking a medication by 1. 20 percentage - Good 2. 10 percentage - Fair 3. less than 10 percentage - PoorTimepoint: HbA1c will be assessed at baseline (Day 0) and after 90 days of treatment.	—

Secondary

Measure	Time frame
Reduction in UKPDS score by 5 percentage of risk .Timepoint: 90 days	—

Countries

India

Contacts

Public ContactDr U CHITRA

Government Siddha Medical College, Chennai

mmsankar2000@gmail.com9445716802

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026